BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INCB123667 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INCB123667\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07559396-10796@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:INCB123667: Phase 1 readout est. (NCT07559396)
DESCRIPTION:INCB123667\, phase 1.\nStudy: A Study to Assess the Safety and 
 Pharmacokinetics of INCB123667 When Administered Orally to Adult Participa
 nts With Severe Renal Impairment or End Stage Renal Disease\nEstimated pri
 mary completion: 4 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/incb123667#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07559396
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559474-10796@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:INCB123667: Phase 1 readout est. (NCT07559474)
DESCRIPTION:INCB123667\, phase 1.\nStudy: A Study to Assess the Safety and 
 Pharmacokinetics of INCB123667 When Administered Orally to Adult Participa
 nts With Moderate or Severe Hepatic Impairment\nEstimated primary completi
 on: 13 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/in
 cb123667#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07559474
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023627-10796@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:INCB123667: Phase 2 readout est. (NCT07023627)
DESCRIPTION:INCB123667\, phase 2\, Ovarian Cancer.\nStudy: A Study of INCB1
 23667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E
 1 Overexpression\nEstimated primary completion: 27 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/incb123667#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023627
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214779-10796@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:INCB123667: Phase 3 readout est. (NCT07214779)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Study to Evaluat
 e INCB123667 Versus Investigator's Choice of Chemotherapy in Participants 
 With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression\nEsti
 mated primary completion: 12 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/incb123667#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07214779
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797283-10796@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:INCB123667: Phase 3 readout est. (NCT07797283)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Study of
  INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Mainte
 nance Therapy in Ovarian Cancer Overexpressing Cyclin E1\nEstimated primar
 y completion: 1 May 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/incb123667#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07797283
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
